1416794-77-8Relevant articles and documents
Discovery of TRPM8 Antagonist (S)-6-(((3-Fluoro-4-(trifluoromethoxy)phenyl)(3-fluoropyridin-2-yl)methyl)carbamoyl)nicotinic Acid (AMG 333), a Clinical Candidate for the Treatment of Migraine
Horne, Daniel B.,Biswas, Kaustav,Brown, James,Bartberger, Michael D.,Clarine, Jeffrey,Davis, Carl D.,Gore, Vijay K.,Harried, Scott,Horner, Michelle,Kaller, Matthew R.,Lehto, Sonya G.,Liu, Qingyian,Ma, Vu V.,Monenschein, Holger,Nguyen, Thomas T.,Yuan, Chester C.,Youngblood, Beth D.,Zhang, Maosheng,Zhong, Wenge,Allen, Jennifer R.,Chen, Jian Jeffrey,Gavva, Narender R.
, p. 8186 - 8201 (2018/09/21)
Transient-receptor-potential melastatin 8 (TRPM8), the predominant mammalian cold-temperature thermosensor, is a nonselective cation channel expressed in a subpopulation of sensory neurons in the peripheral nervous system, including nerve circuitry implicated in migraine pathogenesis: the trigeminal and pterygopalatine ganglia. Genomewide association studies have identified an association between TRPM8 and reduced risk of migraine. This disclosure focuses on medicinal-chemistry efforts to improve the druglike properties of initial leads, particularly removal of CYP3A4-induction liability and improvement of pharmacokinetic properties. A novel series of biarylmethanamide TRPM8 antagonists was developed, and a subset of leads were evaluated in preclinical toxicology studies to identify a clinical candidate with an acceptable preclinical safety profile leading to clinical candidate AMG 333, a potent and highly selective antagonist of TRPM8 that was evaluated in human clinical trials.
